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Substance P and selective neurokinin receptor agonists have been tested for their ability to induce shape change in rabbit platelets. Substance P 
and the NK~ receptor agonist Ac [Arg6,Sar~,Met(O2) ~].substance P (6-11) induced shape change (ECho = 3 and 6 nM, respectively), whereas the 
selective NK,. alienist [Nle~°]-Neurokinin A (4-10) and the selective NK3 agonist [MePheT].Neurokinin B did not show any effect. Moreover, the 
specific NK~ receptor antagonist CP-96,345 selectively and dose-dependently counteracted the effect of substance P or of the NK) receptor agonist 
(ICs0 = 2 and 0.8 nM, respectively), whereas the selective NK: receptor antagonist, SR 48968, had no effect. Unlike for serotonin or low doses 
of ADP, epinephrine did not allow substance P or the NKt receptor agonist o become a proaggregating substance. These data therefore show 
that the NK~ receptor is solely involved in the neurokinin-induced shape change of rabbit platelets. 
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1. INTRODUCTION 
Neurokinins are endogenous peptides present in the 
central and peripheral nervous system [1]. Their func- 
tions have not yet been clearly elucidated, but they seem 
to be involved in a bi-directional communication be- 
tween the immune and the nervous system [1]. Three 
principal types of  natural occurring neurokinins have 
been described: substance P [2,3], uettrckinin A and B 
[4]. The three neurokinins act, with imperfect specificity, 
on three different types of receptors, respectively named 
NK~, NK2 and NKs, which have been cloned, charac- 
terized biochemically as well as pharmacologically [5- 
10]. 
The biological effects of neurokinins have been essen- 
tially described on smooth muscle system (respiratory, 
gastrointestinal, cardiovascular and urinary) and nerv- 
ous system (gland secretion, transmission of painful 
stimuli) [11] but additional properties suggest hat neu- 
rokinins are also involved in immunological and inflam- 
matory process including proliferation of lymphocytes 
T [1], leukoeytes migration, neutrophils degranulation 
[12], phagocytosis [13] and endothelial gap formation 
[12]. 
Moreover, neurokinins produce diverse effects on 
platelets, including shape change [14], potentiation of 
cytotoxicity against Schi~'tosoma man~'ini [15] in vitro 
and intra vessel platelet aggregate formation in vivo 
[12]. Oudat et al. [14] indicated that substance P-in- 
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duced shape change of rabbit platelets was the result of 
a specific interaction of the agonist with a receptor but 
did not further characterize the exact type of receptor 
mediating the interaction of substance P with platelets. 
The aim of this study was thus to demonstrate what 
type of neurokinin receptor was mainly involved in the 
neurokinin-indueed platelet shape change using specific 
neurokinin receptor agonists and antagonists. 
2. MATERIALS AND METHODS 
2.1. Drugs attd materials 
Ac[Arg6,Sar'~,Met(O:)"]-substance P (6-11) (NKt ago), [NIeI(~].Neu. 
rokinin A (4-10) (NK= ago) and [MePheT]-Neurokinia B (NK~ ago) 
were purchased from Novabiochem (L'.-lufelfingen, Switzerland). Sub- 
stance P, serotonin (5-HT) and epinephrine were from Sigma (l'lsl¢ 
d'Abeau, France). Adenosine 5"~iphosphate (ADP) was provided by 
Bochringer Mannheim (Meylan, France). CP-96.345, aselective NKI- 
specific antagonist and SR 48968, a selective N K2-specific antagonist 
were synthesized in the laboratories of Sanofi Recherche (Montpellier, 
France) as previously described [16]. 
2.2. Preparation of platelet.rich plasma 
Blood was withdrawn by venipuncture from male New-Zealand 
rabbit, (4--5 kg, Lago, France). The sample (72 ml) was immediately 
mixed with 8 ml of a 3.8% tri-sodium citrate solution and platelet.rich 
plasma (PRP) was obtained by ccntrifugation (10 rain, 300 x g, 1 ~*C). 
The l~llet was then further centrifuged (2,000 × g, 10 rain) to obtain 
platelet poor plasma (PPP). Platelet concentration of the PRP was 
adjusted to 709,000 cells//zl by adding PPP. ]~RP was then incubated 
at 37"C for 2 h. 
2.3. Measuretnent of platelet shape change and aggregation 
Shape change was measured by the increase of the light absorption 
in an aggrggometer, according to Colman ¢t el. [17], PRP (400/el) was 
placed lbr 2 rain in the ettvette of s dual-channel aggregometer 
(Chrono!og Corp., Havertown, PA) under constant stirrin/~ (900 rpm) 
at 37°C. Then, 4/~1 of a 500 raM EDTA solution (pH 7,4) were added 
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and, 10 s later, shape change was induced by the various agonLsts at 
the indicated concentrations. Shape change was expressed as the i~r- 
cent of maximal light absorption induo~! by IO/~M ADP, in the same 
experimental conditions. 
Aggregation was measured and expressed according to the turbidi- 
metric method of Born and Cross [18]. PRP (400/~i) was placed in the 
aggregometer at 37°C, under constant stirring as described above. The 
various agonists were incubated with the PRP for 1 rain and the 
aggre~tion was induced b#: the addition of epinephrine (10MM). The 
ae~regation was expressed asthe percent of the light transmission. 
where the OD of the PRP was 0% and the OD of the PPP was 100% 
of aggregation. 
3. RESULTS AND DISCUSSION 
Substance P and the selective NK~ receptor agonist 
Ac[Argr,Sarg,Met(O2)ll]-substance P (6-11) (NKI ago) 
induced shape change of rabbit platelets (Fig. 1). This 
effect was significant from the dose of 1-3 nM and 
reached a maximum at the concentration of 1/zM. The 
ECs0 (concentrations which exhibited 50% of the maxi- 
mal effect) of substance P and the NK~ ago were respec- 
tively of 3 and 6 nM. After the addition of 10/~M of 
substance P or the NKt agonist, the observed shape 
change represented =30% of what could be obtained 
after stimulation with ADP or 5-HT at the same dose. 
In contrast, neither [Nle]°]-Neurokinin A (4--10) 
(NK~. ago) nor [MePheT]-Neurokinin B (NK3 ago) did 
show any effect on the shape change of rabbit platelets 
therefore showing that this effect was specific only me- 
diated by the NK~ receptor. 
In order to ascertain such an observation, two neu- 
rokinin receptor antagonists were tested for their ability 
to affect NK~ agonist- or substance P-induced shape 
change. CP-~6,345 is a non-peptide antagonist which 
has been shown to ~pecifically inhibit the binding of 
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Fig, 1. Shape change of the rabbit platelets, induced by neurokinins, 
serotonin and ADP. R~bbit platelet shape change was measured after 
the addition of increasing concentrations f ubstance P (o), NKa ago 
(o), NK_, ago (v), NK~ ago (v), 5-HT ([]) or ADP (11). Results are 
expressed asmean % of shape change obtained with tO/~M ADP 
(n = 4). 
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Fig. 2. Effects of neurokinin antagonists on rabbit platclct shape 
change. Rabbit PRP was incubated for 2 min with the specific NKt 
receptor antagonist CP-96,345 (empty symbols) or the specific NKz 
receptor antagonist SR 48968 (fall symbols) at the indicated concen- 
trations. Shape change was then measured after the addition of i/.tM 
substan¢~ P (circles), 1/.tM NKI ago (trianBles), 10/zM 5-HT (squares) 
or lObtM ADP (diamonds). Results shown are means (n = 4). 
[all]substance P to the NK~ receptor [13]. It also inhib- 
ited the effects of substance P at nanomolar concentra- 
tions in numerous animals model [19]. As shown in Fig. 
2, CP-96,345 counteracted in a dose-dependent manner 
the effect of I / tM substance P or the NK~ agonist with 
IC5o values (concentration which inhibited 50% of the 
effect of the agonist) of  2 and 0.8 aM, respectively. 
These effects were highly specific since CP-96,345 failed 
to inhibit the shape change induced either by 5-HT or 
ADP (10/tM). 
SR 48968 is a non-peptide compound which has been 
recently described to potently and selectively inhibit the 
binding of [J:Sl]NKA to the NK= receptor on various 
cells and tissues without affecting the binding of specific 
agonists of the NK~ and NK~ receptors [20]. These ef- 
fects and their selectivity were recently confirmed in a 
variety of isolated smooth muscle cell preparations [21]. 
In our experimental conditions, SR 48968 did not in- 
hibit substanc~ P- or the NK~ agonist-indueed shape 
change therefore confirming that the substance P-in- 
duced shape change of rabbit platelets was mediated by 
the NK~ receptor. It is noteworthy that neither CP 
96,345 nor SR 48,968 did induce shape change per se. 
As already described in numerous tudies [22], shape 
change of  platelets often precludes to platelet aggrega- 
tion which seems to occur as a consecutive event. In- 
deed, several works from oar laboratory and others [23] 
showed that in rabbit platelets, 5-HT or non-aggregat- 
ing amounts of ADP induced plateleL shape change 
without triggering platelet aggregation which occurred 
in synergy with epinephrine. For these Masons, sub- 
stance P or the selective NK~ agonists were incubated 
in the presence of epinephrine and the aggregating re- 
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sponse of platelets was measured. As already shown 
[24]~ epinephrine (10 aM) did not induce platelet aggre- 
gation by itself but potentiated the aggregating effect of 
5-HT or ADP. In contrast, when platelets were first 
stimulated with substance P or the NKt ago, epineph- 
rine did not allow them to become proaggregating 
agents (data not shown). 
In conclusion, oar study demonstrates that neuroki- 
nin-induced shape change of rabbit platelets is only me- 
diated by the NKt receptor. This shape change is not 
linked to platelet aggregation since epinephrine did not 
synergize with substance P or the NK) agonist to trigger 
platelet aggregation as already shown for other aggre- 
gating agents such as ADP, 5-HT, thromboxane A~ or 
thrombin. However, further in rive studies in animal 
models of" thrombosis with selective NKj receptor an- 
tagonists, will indicate if this property of neurokinins is 
related to some thrombotic event. 
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